Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

BACKGROUND: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and most...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, In Hee, Lee, Soo Jung, Lee, Jeeyeon, Jung, Jin Hyang, Park, Ho Yong, Jeong, Shin Young, Lee, Sang-woo, Chae, Yee Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667770/
https://www.ncbi.nlm.nih.gov/pubmed/33198673
http://dx.doi.org/10.1186/s12885-020-07505-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667770/
https://www.ncbi.nlm.nih.gov/pubmed/33198673
http://dx.doi.org/10.1186/s12885-020-07505-w

Ejemplares similares